Chitin-based wound hemostatic dressing
By using chitin and nanofiber materials combined with modified polylactic acid encapsulator in trauma hemostatic dressings, a synergistic pharmaceutical composition is formed, which solves the shortcomings of existing dressings in hemostasis, anti-infection and promoting healing, and achieves the goal of achieving More efficient hemostasis and long-term antibacterial effects.
Patent Information
- Application Number
- CN202310244086.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-10
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-03-10
AI Technical Summary
The existing trauma hemostasis dressings have shortcomings in hemostasis performance, anti-infection effects and pro-healing effects, and it is necessary to develop safer and more efficient dressings.
Dressing made of chitin-based nanofiber materials, by modifying polylactic acid as the encapsulator of the pharmaceutical composition, combined with components such as erythrone, flavanol, ε-polylysine, etc., to form synergistic effects. Microcapsules improve hemostasis effect, and enhance antioxidant and antibacterial effects by oxidizing ingredients such as Artemisia annua polysaccharide and catechin, and promote wound repair.
It significantly improves hemostasis and anti-infection ability, achieves sustained and long-term release of drugs, promotes wound healing, has excellent antibacterial and pro-repair effects, and exceeds the performance of conventional dressings.
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of trauma hemostatic dressings, and in particular to a chitin-based trauma hemostatic dressing. Background Art
[0002] Wound dressings are materials used to bandage wounds, covering sores, wounds or other lesions. The types of wound dressings mainly include passive dressings, interactive dressings and bioactive dressings. Passive dressings are traditional dressings that passively cover the wound surface and absorb exudate, providing limited protection for the wound surface. Interactive dressings interact with the wound surface in various forms, such as absorbing exudate and toxic substances, allowing gas exchange, and thus creating an ideal environment for healing; they generally have a barrier outer layer structure to prevent the invasion of microorganisms in the environment and prevent cross-infection of the wound surface.
[0003] Bioactive dressings are a new type of wound dressing that mainly exerts its main effects based on bioactive substances. They are composite dressings made of polymer materials and biological materials through high-tech methods, and are a hot topic in the development and research of wound dressings. Biosynthetic dressings have a double-layer structure. The outer layer uses polymer materials to provide a barrier function equivalent to the epidermis; the main materials used for the inner layer are collagen, chitosan wound dressings and calcium alginate and other active substances, which have biocompatibility, good water absorption, breathability, adhesion, and antibacterial and hemostatic effects. It can absorb wound exudate to ensure sufficient drainage, and can also retain part of the exudate in the dressing to maintain a local moist environment that imitates the physiological healing of the wound, which is conducive to the regeneration of wound granulation tissue and epithelial cells and accelerates wound healing. Some substances that are conducive to wound healing, such as drugs, cytokines, growth factors, etc., can also be added to synthetic dressings to form various dressings such as drug dressings, cytokine dressings, and growth factor dressings. At present, conventional trauma hemostatic dressings still need to be improved in terms of hemostatic performance, anti-infection effect, and healing promotion effect. In this case, how to develop safer and more effective trauma hemostatic dressings is a technical problem to be solved in this field. Summary of the invention
[0004] The present invention aims to provide a chitin-based trauma hemostatic dressing to address the technical defects of the prior art, so as to solve the technical problems that conventional trauma hemostatic dressings need to be improved in terms of hemostatic performance, anti-infection effect, and healing promotion effect.
[0005] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:
[0006] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; wherein the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following components in parts by weight: 10 to 12 parts of chitosan, 1 to 3 parts of dracorubin, 0.5 to 2 parts of flavanol, 1 to 2 parts of ε-polylysine, 0.2 to 0.3 parts of polyglutamic acid, 0.3 to 2 parts of inositol phosphate, 0.2 to 0.5 parts of catechin, 0.8 to 1 parts of quercetin, 0.3 to 0.6 parts of oxidized artemisia annua polysaccharide, 0.8 to 1.2 parts of L-polylactic acid, 0.1 to 0.2 parts of isoergoside, and 0.05 to 0.2 parts of laurocapram.
[0007] Preferably, the pharmaceutical composition further comprises the following ingredients in parts by weight: 0.3 to 0.5 parts of hydroxymethylcoumarin.
[0008] Preferably, the pharmaceutical composition further comprises the following ingredients in parts by weight: 0.5 to 0.7 parts of glycyl-L-threonine.
[0009] Preferably, the pharmaceutical composition further comprises the following ingredients in parts by weight: 0.3 to 0.5 parts of high theaflavins,
[0010] Preferably, the pharmaceutical composition further comprises the following ingredients in parts by weight: 1 to 3 parts of keratin.
[0011] Preferably, the pharmaceutical composition further comprises the following ingredients in parts by weight: 0.6 to 0.8 parts of cetearyl alcohol polyether.
[0012] Preferably, the pharmaceutical composition is composed of the following ingredients in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisinin, 1 part of L-polylactic acid, 0.15 parts of isoergoside, and 0.08 parts of laurocapram.
[0013] Preferably, the pharmaceutical composition is composed of the following ingredients in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisinin, 1 part of L-polylactic acid, 0.15 parts of isoergoside, 0.08 parts of laurocapram, 0.4 parts of hydroxymethylcoumarin, 0.6 parts of glycyl-L-threonine, 0.4 parts of homotheaflavins, 2 parts of keratin, and 0.7 parts of cetearyl alcohol polyether.
[0014] Preferably, the nanofiber material is made of PA6 and PET as raw materials, which are first made into silk material by a spunbond method, then stretched by CO2 laser heating, and finally opened and entangled to obtain the fiber material.
[0015] Preferably, the core-shell structure of the active substance has a diameter not exceeding 100 nm.
[0016] The present invention provides a wound hemostatic dressing based on chitin. The technical solution uses a core-shell structure to construct a microcapsule with a sustained-release effect, and uses nanofiber materials to immobilize the microcapsules, and on this basis improves the compounding scheme of the pharmaceutical composition. Specifically, the present invention uses chitosan as the main component, and forms a synergistic effect with dracorubin, flavanols, and ε-polylysine, which not only improves the hemostatic effect, but also has a good antibacterial effect. At the same time, thanks to the antioxidant properties of ingredients such as oxidized artemisinin polysaccharide, hydroxymethylcoumarin, and laurocapram, it helps to ensure the anti-infection effect. Moreover, the present invention uses polyglutamic acid as the core, and forms a compounding scheme with ingredients such as phosphate inositol, glycyl-L-threonine, keratin, etc., to supplement ingredients such as amino acids and creatinine for wound repair, which helps to promote wound repair. In addition, the present invention uses modified polylactic acid to embed the pharmaceutical composition, and the resulting unit body not only has good dispersibility, but also has a sustained-release effect. Compared with the prior art, the present invention fully improves the hemostatic and anti-infection effects of wound dressings, while achieving a certain repair-promoting effect, and has outstanding technical advantages. DETAILED DESCRIPTION
[0017] The specific embodiments of the present invention will be described in detail below. In order to avoid too much unnecessary details, the well-known structures or functions will not be described in detail in the following examples. The approximate language used in the following examples can be used for quantitative expression, indicating that the quantity can be allowed to have a certain change without changing the basic function. Unless otherwise defined, the technical and scientific terms used in the following examples have the same meaning as those generally understood by those skilled in the art to which the present invention belongs.
[0018] Example 1
[0019] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following components in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisia annua polysaccharide, 1 part of L-polylactic acid, 0.15 parts of isoergoside and 0.08 parts of laurocapram.
[0020] Example 2
[0021] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following ingredients in parts by weight: 12 parts of chitosan, 3 parts of dracorubin, 2 parts of flavanols, 2 parts of ε-polylysine, 0.3 parts of polyglutamic acid, 2 parts of inositol phosphate, 0.5 parts of catechins, 1 part of quercetin, 0.6 parts of oxidized artemisinin, 1.2 parts of L-polylactic acid, 0.2 parts of isoergoside and 0.2 parts of laurocapram.
[0022] Example 3
[0023] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following ingredients in parts by weight: 10 parts of chitosan, 1 part of dracorubin, 0.5 parts of flavanols, 1 part of ε-polylysine, 0.2 parts of polyglutamic acid, 0.3 parts of inositol phosphate, 0.2 parts of catechins, 0.8 parts of quercetin, 0.3 parts of oxidized artemisinin polysaccharide, 0.8 parts of L-polylactic acid, 0.1 parts of isoergoside, and 0.05 parts of laurocapram.
[0024] Example 4
[0025] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following components in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisia annua polysaccharide, 1 part of L-polylactic acid, 0.15 parts of isoergoside, 0.08 parts of laurocapram, 0.4 parts of hydroxymethylcoumarin, 0.6 parts of glycyl-L-threonine, 0.4 parts of homotheaflavins, 2 parts of keratin, and 0.7 parts of cetearyl alcohol polyether.
[0026] Example 5
[0027] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following components in parts by weight: 12 parts of chitosan, 3 parts of dracorubin, 2 parts of flavanols, 2 parts of ε-polylysine, 0.3 parts of polyglutamic acid, 2 parts of inositol phosphate, 0.5 parts of catechins, 1 part of quercetin, 0.6 parts of oxidized artemisia annua polysaccharide, 1.2 parts of L-polylactic acid, 0.2 parts of isoergosterol, 0.2 parts of laurocapram, 0.5 parts of hydroxymethylcoumarin, 0.7 parts of glycyl-L-threonine, 0.5 parts of homotheaflavins, 3 parts of keratin, and 0.8 parts of cetearyl alcohol polyether.
[0028] Example 6
[0029] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following components in parts by weight: 12 parts of chitosan, 3 parts of dracorubin, 2 parts of flavanols, 2 parts of ε-polylysine, 0.3 parts of polyglutamic acid, 2 parts of inositol phosphate, 0.5 parts of catechins, 1 part of quercetin, 0.6 parts of oxidized artemisia annua polysaccharide, 1.2 parts of L-polylactic acid, 0.2 parts of isoergosterol, 0.2 parts of laurocapram, 0.3 parts of hydroxymethylcoumarin, 0.5 parts of glycyl-L-threonine, 0.3 parts of homotheaflavins, 1 part of keratin, and 0.6 parts of cetearyl alcohol polyether.
[0030] Example 7
[0031] A chitosan-based trauma hemostatic dressing comprises a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; the active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell, wherein the pharmaceutical composition comprises the following components in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisia annua polysaccharide, 1 part of L-polylactic acid, 0.15 parts of isoergoside, 0.08 parts of laurocapram, 0.4 parts of hydroxymethylcoumarin, 0.6 parts of glycyl-L-threonine, 0.4 parts of homotheaflavins, 2 parts of keratin, and 0.7 parts of cetearyl alcohol polyether. The nanofiber material is made of PA6 and PET as raw materials, firstly made into silk material by spunbonding method, then stretched by CO2 laser heating, and then opened and entangled to obtain fiber material. The core-shell structure of the active substance has a diameter of no more than 100nm.
[0032] 1. Determination of sustained release effect
[0033] A group a (Example 1), a group b (Example 7), and a group c (commercially available conventional wound dressing) were set up, and the samples were placed in a PBS solution with a pH of 7.5. Samples were taken every 4 hours at the beginning, every 12 hours after 12 hours, and every 24 hours after 24 hours, with 2 ml of sample taken each time, to test the release effect of the drug components.
[0034] The Example 1 and Example 7 groups have a sustained release effect of the drug, and the drug release time is as long as 120 hours; the drug release time of the commercially available conventional wound dressing group is 48 hours; because the ordinary dressing has no sustained release effect and the sustained release effect is very weak, the release rate is close to 80% within 4 hours, and the drug is completely released after 48 hours. The experimental results show that the drug release rate of the present invention is gentle and the release time is long.
[0035] 2. Antibacterial ring test
[0036] A group a (Example 1), a group b (Example 7), and a group c (commercially available conventional wound dressing) were set up, and the samples were placed in a solid culture medium coated with Staphylococcus aureus and kept at 37° C. overnight. An antibacterial ring test was performed to observe the antibacterial effects of the samples.
[0037] Sample c has no antibacterial ring, indicating that conventional wound dressings on the market have no antibacterial effect; the diameter of the antibacterial ring of sample b is 28.8 mm, which shows that the dressing of Example 7 has a good antibacterial effect; the diameter of the antibacterial ring of sample a is 30.2 mm, which shows that the dressing of Example 1 has a certain antibacterial effect. Since the drug is formed into microcapsules through the embedding structure, the base component has an impact on the release effect, so its antibacterial effect is slightly better, but both meet the antibacterial requirements, and in view of its sustained release effect, its long-term antibacterial effect will not form a large difference.
[0038] 3. Hemostatic effect experiment
[0039] The following examples 1-7 and the comparative example (commercially available conventional wound dressing) were applied to hemostasis of the femoral artery of pigs, and the wound healing time was detected every 1 minute starting from 3 minutes (the wound healing time only counted the wound healing time of the pigs whose wounds healed within 20 minutes, and the unhealed pigs were not counted). The specific method is as follows: 50 100±2kg Landrace pigs (male-female ratio is about 1:1, and there is no significant difference between the examples) were selected for each example; a femoral artery incision of 3±0.2cm in length was made with a thin blade; the wound was immediately covered with a medical dressing and finger pressure was performed. The specific test data are shown in the following table.
[0040] Table 1 Hemostatic effect experimental results
[0041] Number of experimental subjects Wound healing number Wound healing time (min) Example 1 50 48 4.5 Example 2 50 47 4.2 Example 3 50 50 3.8 Example 4 50 50 3.2 Example 5 50 49 3.4 Example 6 50 48 3.3 Example 7 50 50 3.1 Comparative Example 50 32 12.4
[0042] Note: Wound healing refers to no bleeding within 10 seconds without pressure on the wound.
[0043] The above experimental results show that the trauma hemostatic dressing of the present invention has a good hemostatic effect, and the effective rate and hemostasis time are better than those of conventional commercially available products. Moreover, the preferred technical scheme of the present invention improves the hemostatic effect to a certain extent, reflecting a synergistic effect.
[0044] The embodiments of the present invention are described in detail above, but the contents are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the scope of the present invention shall be included in the protection scope of the present invention.
Claims
1. A chitin-based trauma hemostatic dressing, comprising a substrate and an active substance attached to the substrate, wherein the substrate is a nanofiber material; characterized in that: The active substance comprises a shell composed of modified polylactic acid and a pharmaceutical composition wrapped in the shell. The pharmaceutical composition comprises the following ingredients in parts by weight: 10 to 12 parts of chitosan, 1 to 3 parts of dracorubin, 0.5 to 2 parts of flavanol, 1 to 2 parts of ε-polylysine, 0.2 to 0.3 parts of polyglutamic acid, 0.3 to 2 parts of inositol phosphate, 0.2 to 0.5 parts of catechins, 0.8 to 1 parts of quercetin, 0.3 to 0.6 parts of oxidized artemisia annua polysaccharide, 0.8 to 1.2 parts of L-polylactic acid, 0.1 to 0.2 parts of isoergoside, and 0.05 to 0.2 parts of laurocapram.
2. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition further comprises the following ingredients in parts by weight: 0.3 to 0.5 parts of hydroxymethylcoumarin.
3. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition further comprises the following ingredients in parts by weight: 0.5 to 0.7 parts of glycyl-L-threonine.
4. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition further comprises the following ingredients in parts by weight: 0.3 to 0.5 parts of high theaflavins.
5. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition further comprises the following ingredients in parts by weight: 1 to 3 parts of keratin.
6. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition further comprises the following ingredients in parts by weight: 0.6 to 0.8 parts of cetearyl alcohol polyether.
7. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition is composed of the following ingredients in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisinin, 1 part of L-polylactic acid, 0.15 parts of isoergoside, and 0.08 parts of laurocapram.
8. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The pharmaceutical composition is composed of the following ingredients in parts by weight: 11 parts of chitosan, 2 parts of dracorubin, 1.2 parts of flavanols, 1.5 parts of ε-polylysine, 0.24 parts of polyglutamic acid, 1.1 parts of inositol phosphate, 0.4 parts of catechins, 0.9 parts of quercetin, 0.5 parts of oxidized artemisinin, 1 part of L-polylactic acid, 0.15 parts of isoergoside, 0.08 parts of laurocapram, 0.4 parts of hydroxymethylcoumarin, 0.6 parts of glycyl-L-threonine, 0.4 parts of homotheaflavins, 2 parts of keratin, and 0.7 parts of cetearyl alcohol polyether.
9. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The nanofiber material is made of PA6 and PET as raw materials, which are first made into silk material by a spunbond method, then stretched by CO2 laser heating, and finally opened and entangled to obtain the fiber material.
10. The chitin-based hemostatic dressing for trauma according to claim 1, characterized in that: The core-shell structure of the active substance has a diameter not exceeding 100 nm.
Citation Information
Patent Citations
Method for synthesizing creatinol-o-phosphate
CN102584890A
Burn cream and preparation method thereof
CN103610869A
Double-network hydrogel wound dressing and preparation method thereof
CN112876700A
